Joshua N Gustine

List of Publications by Year
in descending order

34 papers	1,700 citations	394421 19 h-index	395702 33 g-index
34 all docs	34 docs citations	34 times ranked	1829 citing authors

#	Article	IF	Citations
1	Natural history of WaldenstrÃ¶m macroglobulinemia following acquired resistance to ibrutinib monotherapy. Haematologica, 2022, 107, 1163-1171.	3.5	11
2	Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia. Leukemia, 2022, 36, 532-539.	7.2	50
3	Response and survival predictors in a cohort of 319 patients with WaldenstrÃ¶m macroglobulinemia treated with ibrutinib monotherapy. Blood Advances, 2022, 6, 1015-1024.	5.2	12
4	Predictors of hematologic response and survival with stem cell transplantation in <scp>AL</scp> amyloidosis: A 25â€year longitudinal study. American Journal of Hematology, 2022, 97, 1189-1199.	4.1	12
5	Partial response or better at sixÂmonths is prognostic of superior progressionâ€free survival in WaldenstrÃ¶m macroglobulinaemia patients treated with ibrutinib. British Journal of Haematology, 2021, 192, 542-550.	2.5	8
6	Immunopathology of Hyperinflammation in COVID-19. American Journal of Pathology, 2021, 191, 4-17.	3.8	372
7	Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With WaldenstrÃ¶m Macroglobulinemia. Journal of Clinical Oncology, 2021, 39, 565-575.	1.6	98
8	Bone marrow involvement and subclonal diversity impairs detection of mutated CXCR4 by diagnostic nextâ€generation sequencing in WaldenstrÃ¶m macroglobulinaemia. British Journal of Haematology, 2021, 194, 730-733.	2.5	16
9	Cellâ€free <scp>DNA</scp> analysis for detection of <scp>MYD88^{L265P}</scp> and <scp>CXCR4^{S338X}</scp> mutations in <scp>W</scp>aldenstrÃ¶m macroglobulinemia. American Journal of Hematology, 2021, 96, E250-E253.	4.1	8
10	Diagnostic Next-generation Sequencing Frequently Fails to Detect MYD88L265P in WaldenstrÃ¶m Macroglobulinemia. HemaSphere, 2021, 5, e624.	2.7	15
11	Response and Survival Outcomes to Ibrutinib Monotherapy for Patients With WaldenstrÃ¶m Macroglobulinemia on and off Clinical Trials. HemaSphere, 2020, 4, e363.	2.7	12
12	Genomic Landscape of WaldenstrÃ¶m Macroglobulinemia and Its Impact on Treatment Strategies. Journal of Clinical Oncology, 2020, 38, 1198-1208.	1.6	103
13	<scp>CXCR4</scp> mutational status does not impact outcomes in patients with <scp>W</scp>aldenstrÃ¶m macroglobulinemia treated with proteasome inhibitors. American Journal of Hematology, 2020, 95, E95-E98.	4.1	12
14	A matched case-control study comparing features, treatment and outcomes between patients with non-IgM lymphoplasmacytic lymphoma and WaldenstrÃ¶m macroglobulinemia. Leukemia and Lymphoma, 2020, 61, 1388-1394.	1.3	9
15	CXCR4 mutation subtypes impact response and survival outcomes in patients with WaldenstrÃ¶m macroglobulinaemia treated with ibrutinib. British Journal of Haematology, 2019, 187, 356-363.	2.5	73
16	CXCR4 S338X clonality is an important determinant of ibrutinib outcomes in patients with WaldenstrÃ¶m macroglobulinemia. Blood Advances, 2019, 3, 2800-2803.	5.2	27
17	Cell Wall Hydrolytic Enzymes Enhance Antimicrobial Drug Activity Against Mycobacterium. Current Microbiology, 2019, 76, 398-409.	2.2	5
18	Long survival in patients with WaldenstrÃ¶m macroglobulinaemia diagnosed at a young age. British Journal of Haematology, 2019, 185, 799-802.	2.5	4

#	Article	IF	Citations
19	Low levels of von Willebrand markers associate with high serum IgM levels and improve with response to therapy, in patients with WaldenstrÃ¶m macroglobulinaemia. British Journal of Haematology, 2019, 184, 1011-1014.	2.5	19
20	Response and survival for primary therapy combination regimens and maintenance rituximab in WaldenstrÃ¶m macroglobulinaemia. British Journal of Haematology, 2018, 181, 77-85.	2.5	41
21	Prospective Clinical Trial of Ixazomib, Dexamethasone, and Rituximab as Primary Therapy in WaldenstrÃ¶m Macroglobulinemia. Clinical Cancer Research, 2018, 24, 3247-3252.	7.0	57
22	Fitting mSMART Into the Current Clinical Management of WaldenstrÃ¶m Macroglobulinemia. JAMA Oncology, 2018, 4, 744.	7.1	0
23	<scp>MYD</scp>88 wildâ€type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, andÂoverall survival. British Journal of Haematology, 2018, 180, 374-380.	2.5	83
24	Comparing apples to oranges: A commentary on the <scp>M</scp>ayo study of <scp>MYD</scp>88 significance in <scp>W</scp>aldenstrom's macroglobulinemia.. American Journal of Hematology, 2018, 93, E69-E71.	4.1	1
25	Ibrutinib Monotherapy in Symptomatic, Treatment-NaÃ¯ve Patients With WaldenstrÃ¶m Macroglobulinemia. Journal of Clinical Oncology, 2018, 36, 2755-2761.	1.6	142
26	Insights into the genomic landscape of MYD88 wild-type WaldenstrÃ¶m macroglobulinemia. Blood Advances, 2018, 2, 2937-2946.	5.2	72
27	Acquired mutations associated with ibrutinib resistance in WaldenstrÃ¶m macroglobulinemia. Blood, 2017, 129, 2519-2525.	1.4	115
28	Serum IgM level as predictor of symptomatic hyperviscosity in patients with WaldenstrÃ¶m macroglobulinaemia. British Journal of Haematology, 2017, 177, 717-725.	2.5	58
29	IgM myeloma: A multicenter retrospective study of 134 patients. American Journal of Hematology, 2017, 92, 746-751.	4.1	45
30	To select or not to select? The role of Bâ€cell selection in determining the <scp>MYD</scp>88 mutation status in WaldenstrÃ¶m Macroglobulinaemia. British Journal of Haematology, 2017, 176, 822-824.	2.5	22
31	Idelalisib in WaldenstrÃ¶m macroglobulinemia: high incidence of hepatotoxicity. Leukemia and Lymphoma, 2017, 58, 1002-1004.	1.3	31
32	Prospective, Multicenter Clinical Trial of Everolimus as Primary Therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214). Clinical Cancer Research, 2017, 23, 2400-2404.	7.0	23
33	Transcriptome sequencing reveals a profile that corresponds to genomic variants in WaldenstrÃ¶m macroglobulinemia. Blood, 2016, 128, 827-838.	1.4	91
34	Histological transformation to diffuse large Bâ€cell lymphoma in patients with WaldenstrÃ¶m macroglobulinemia. American Journal of Hematology, 2016, 91, 1032-1035.	4.1	53